navdeep pal - google scholar citations
TRANSCRIPT
1/16/2017 Navdeep Pal - Google Scholar Citations
https://scholar.google.com/citations?user=lQ3-LBMAAAAJ&hl=en&oi=ao 1/2
Navdeep PalMcKesson Specialty HealthStatistics, Data Science, Clinical Research
Google ScholarCitation indices All Since 2012Citations 39 39hindex 3 3i10index 2 2
Title 1–17 Cited by Year
Overall survival after pelvic exenteration for gynecologic malignancySN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ...Gynecologic oncology 134 (3), 546551
21 2014
PTEN loss is a contextdependent outcome determinant in obese and nonobeseendometrioid endometrial cancer patientsSN Westin, Z Ju, RR Broaddus, C Krakstad, J Li, N Pal, KH Lu, ...Molecular oncology 9 (8), 16941703
10 2015
Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.SN Westin, ML Smart, N Pal, DL Urbauer, F Janku, JJ Wheler, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 2611
3 2013
Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treatcomplex atypical hyperplasia and grade 1 endometrioid endometrial cancerS Westin, C Sun, R Broaddus, N Pal, V Nath, D Urbauer, K Schmeler, ...Gynecologic Oncology 125, S9
3 2012
Challenging the paradigm of progesteroneonly therapy for early endometrialcancer: Results of a prospective trial of the levonorgestrel intrauterine systemSN Westin, CCL Sun, R Broaddus, N Pal, M Woodall, D Urbauer, ...Gynecologic Oncology 141, 1819
1 2016
PTEN loss as a contextdependent determinant of patient outcomes in obese andnonobese endometrioid endometrial cancer patients.Z Ju, SN Westin, R Broaddus, J Li, N Pal, KH Lu, RL Coleman, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 5521
1 2013
Obesity significantly reduces the sentinel lymph node detection rate in women withendometrial cancerPT Soliman, AM Nick, CCL Sun, S Dioun, N Pal, M Abdelwahab, ...Gynecologic Oncology 141, 31
2016
PHASE I TRIAL OF CARBOPLATIN, BEVACIZUMAB, AND TEMSIROLIMUS INADVANCED SOLID TUMORSS Westin, M Castaneda, N Pal, D Urbauer, F Janku, J Wheler, S PihaPaul, ...INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 25 (9), 365365
2015
Sa1416 Differences in ERCP Related Practice Patternsan Electronic SurveyG Syal, N Pal, R Rego, S DangGastrointestinal Endoscopy 81 (5), AB205AB206
2015
Platinumfree interval is a predictor of survival for recurrent, advancedstage uterinepapillary serous carcinomaLL Holman, LE Dockery, PT Soliman, N Pal, AH Klopp, R Broaddus, ...Gynecologic Oncology 137, 159160
2015
1/16/2017 Navdeep Pal - Google Scholar Citations
https://scholar.google.com/citations?user=lQ3-LBMAAAAJ&hl=en&oi=ao 2/2
Title 1–17 Cited by Year
Factors prognostic of survival in advanced stage uterine papillary serous carcinomaN PalTHE UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH
2015
Importance of platinum sensitivity and treatment modality in advancedstage uterinepapillary serous carcinomaL Holman, P Soliman, N Pal, N Balakrishnan, A Klopp, R Broaddus, ...Gynecologic Oncology 130 (1), e79
2013
Neoadjuvant chemotherapy in stage IV uterine papillary serous carcinomaL Holman, P Soliman, N Pal, H Mhadgut, A Klopp, R Broaddus, N Fleming, ...Gynecologic Oncology 130 (1), e82
2013
KRAS mutation in endometrial and ovarian cancers: Preliminary data on associationwith phenotype and clinical outcome in primary diseaseS Westin, C Sun, N Pal, F Janku, A Tsimberidou, G Falchook, D Hong, ...Gynecologic Oncology 130 (1), e162
2013
Pathologic distribution of disease at the time of interval debulking versus primarytumor reduction in women with primary peritoneal, ovarian, or Fallopian tubecarcinoma.TM Zaid, M Huang, AJ Brown, N Balakrishnan, H Mhadgut, N Pal, C Wei, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 5584
2013
Longterm survival in advancedstage uterine papillary serous carcinoma.LL Holman, DA Iglesias, PT Soliman, N Pal, A Klopp, R Broaddus, T Ayeni, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 5596
2013
Retrospective assesment of the levonorgestrel intrauterine device to treat complexatypical hyperplasia and early endometrioid endometrial cancerN Pal
2012
Dates and citation counts are estimated and are determined automatically by a computer program.